Tonix Pharma Begins Phase 2 OASIS Trial

The latest update is out from Tonix Pharma ( (TNXP) ).

On May 21, 2025, Tonix Pharma announced the dosing of the first patient in the Phase 2 OASIS trial, which aims to evaluate the TNX-102 SL product candidate for reducing acute stress reaction and disorder. Sponsored by the University of North Carolina Institute for Trauma Recovery and supported by a $3 million grant from the U.S. Department of Defense, the trial will involve approximately 180 motor vehicle collision trauma survivors in the U.S., assessing the safety and efficacy of TNX-102 SL compared to a placebo.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Spark’s Take on TNXP Stock

According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.

Tonix Pharma’s stock score reflects a company in its growth phase with substantial revenue increases and strategic advancements in product development. However, significant challenges remain in profitability and cash flow sustainability, necessitating ongoing external funding. Positive corporate events provide some optimism, yet weak technical indicators and valuation concerns cap the overall score.

To see Spark’s full report on TNXP stock, click here.

More about Tonix Pharma

Tonix Pharma operates in the pharmaceutical industry, focusing on the development of innovative therapeutics. The company’s primary product under investigation is TNX-102 SL, which is aimed at addressing neuropsychiatric conditions.

Average Trading Volume: 1,363,373

Technical Sentiment Signal: Sell

Current Market Cap: $194.8M

Find detailed analytics on TNXP stock on TipRanks’ Stock Analysis page.